NCT05724589 is a NA clinical trial of Epidermal Growth Factor in Aging, sponsored by Institute of Dermatology, Thailand.

Who is sponsoring NCT05724589?

NCT05724589 is sponsored by Institute of Dermatology, Thailand.

What drugs are being tested in NCT05724589?

Interventions in NCT05724589: Epidermal Growth Factor.

Is NCT05724589 still recruiting?

NCT05724589 is currently completed. Last updated 31 July 2025.

Are results published for NCT05724589?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-07-31 · How we verify

NCT05724589

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles.

Completed NA Results posted Last updated 31 July 2025

What this trial tests

NA trial testing Epidermal Growth Factor in Aging in 28 participants. Completed in 12 December 2024.

Timeline

30 January 2023

Primary endpoint
5 June 2024

12 December 2024

Quick facts

Lead sponsor	Institute of Dermatology, Thailand
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	30 January 2023
Primary completion	5 June 2024
Estimated completion	12 December 2024
Sites	1 location across Thailand

Drugs / interventions tested

Epidermal Growth Factor — full drug profile →

Conditions studied

Aging — all drugs for Aging →

Sponsor

Institute of Dermatology, Thailand

Who can join

Adults 40 to 65, any sex, with Aging. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Facial Skin Hydration Primary · 4 months (Baseline, Week 8, Week 12, Week 16)

Facial skin hydration was measured using a Corneometer, which provides readings in arbitrary units (a.u.). Measurements were taken at baseline (Day 0), Week 8, Week 12, and Week 16 under standardized environmental and procedural conditions to ensure reliability and accuracy. Higher values indicate better skin hydration, while lower values indicate increased dryness.

Baseline

Group	Value	95% CI
Epidermal Growth Factor Serum Application	56.043	± 1.900

8 weeks

Group	Value	95% CI
Epidermal Growth Factor Serum Application	58.300	± 1.567

12 weeks

Group	Value	95% CI
Epidermal Growth Factor Serum Application	55.852	± 1.583

16 weeks

Group	Value	95% CI
Epidermal Growth Factor Serum Application	58.714	± 1.568

Transepidermal Water Loss Primary · 4 months

measured by tewameter on day 0, then at 8, 12, and 16 weeks.

Baseline

Group	Value	95% CI
Epidermal Growth Factor Serum Application	11.815	± 1.221

8 weeks

Group	Value	95% CI
Epidermal Growth Factor Serum Application	8.761	± 0.623

12 weeks

Group	Value	95% CI
Epidermal Growth Factor Serum Application	8.400	± 0.516

16 weeks

Group	Value	95% CI
Epidermal Growth Factor Serum Application	8.160	± 0.559

Facial Skin Elasticity (R2 Parameter Via Cutometer) Primary · Baseline, Week 8, Week 12, Week 16

Skin elasticity was assessed using a Cutometer with the R2 parameter (Ua/Uf), which measures gross elasticity. R2 values range from 0 to 1.0, with higher values indicating better skin elasticity. Measurements were collected under standardized conditions at Baseline (Day 0), Week 8, Week 12, and Week 16.

Baseline

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0.596	± 0.016

8 wk

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0.596	± 0.013

12 wk

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0.584	± 0.012

16 wk

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0.553	± 0.014

Facial Skin Wrinkles Primary · 4 months

Visioscan measurements were taken at baseline, then at 8, 12, and 16 weeks by using a 4-grade percentage wrinkle improvement scale.

baseline

Group	Value	95% CI
Epidermal Growth Factor Serum Application	1	± 0

8 wk

Group	Value	95% CI
Epidermal Growth Factor Serum Application	1	± 0

12 wk

Group	Value	95% CI
Epidermal Growth Factor Serum Application	1	± 0

16 wk

Group	Value	95% CI
Epidermal Growth Factor Serum Application	1	± 0

Facial Melanin Index Primary · 4 months

Facial pigmentation was assessed using the Mexameter, which measures melanin content via light absorption and reflection. The device reports values on a scale from 0 to 999, where higher values represent greater melanin concentration. Measurements were collected at standardized facial sites at Baseline, Week 8, Week 12, and Week 16. Higher scores indicate worse pigmentation.

Baseline

Group	Value	95% CI
Epidermal Growth Factor Serum Application	244.118	± 10.186

8 weeks

Group	Value	95% CI
Epidermal Growth Factor Serum Application	246.296	± 8.955

12 weeks

Group	Value	95% CI
Epidermal Growth Factor Serum Application	243.605	± 10.074

16 weeks

Group	Value	95% CI
Epidermal Growth Factor Serum Application	240.660	± 9.838

Overall Facial Skin Appearance (Photo Evaluation Using SGAIS) Primary · 4 months

Facial skin appearance was evaluated using the Subject Global Aesthetic Improvement Scale (SGAIS), a 5-point scale where higher scores indicate greater improvement. Scores were assigned by two board-certified dermatologists who assessed photographs taken by the Visia-CR imaging system at Baseline, Week 8, Week 12, and Week 16. SGAIS scoring definition: 1 = Worse, 2 = Mild improvement (\<25%), 3 = Moderate (25-49%), 4 = Much improved (50-74%), 5 = Very much improved (≥75%).

8 weeks Doctor 1 : score 1

Group	Value	95% CI
Epidermal Growth Factor Serum Application	10

8 weeks Doctor 1 : score 2

Group	Value	95% CI
Epidermal Growth Factor Serum Application	18

8 weeks Doctor 1 : score 3

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

8 weeks Doctor 1 : score 4

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

8 weeks Doctor 2 : score 1

Group	Value	95% CI
Epidermal Growth Factor Serum Application	12

8 weeks Doctor 2 : score 2

Group	Value	95% CI
Epidermal Growth Factor Serum Application	16

8 weeks Doctor 2 : score 3

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

8 weeks Doctor 2 : score 4

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

Subject Satisfaction in Improving Skin Hydration, Elasticity, Wrinkles, and Pigmentation Secondary · 4 months

Using a quartile grading system, (0 = unsatisfied), (1 = slightly satisfied), (2 = satisfied), and (3 = very satisfied)

8 weeks : very satisfied

Group	Value	95% CI
Epidermal Growth Factor Serum Application	10

8 weeks : satisfied

Group	Value	95% CI
Epidermal Growth Factor Serum Application	18

8 weeks : slightly satisfied

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

8 weeks : unsatisfied

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

8 weeks : NA (loss follow up)

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

12 weeks : very satisfied

Group	Value	95% CI
Epidermal Growth Factor Serum Application	5

12 weeks : satisfied

Group	Value	95% CI
Epidermal Growth Factor Serum Application	21

12 weeks : slightly satisfied

Group	Value	95% CI
Epidermal Growth Factor Serum Application	1

Adverse Events Secondary · 4 months

Adverse events were systematically monitored at 2, 4, 8, 12, and 16 weeks post-treatment initiation.

2 weeks : No adverse event

Group	Value	95% CI
Epidermal Growth Factor Serum Application	28

2 weeks : Yes adverse event

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

2 weeks : Data missing

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

4 weeks : No adverse event

Group	Value	95% CI
Epidermal Growth Factor Serum Application	28

4 weeks : Yes adverse event

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

4 weeks :Data missing

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

8 weeks : No adverse event

Group	Value	95% CI
Epidermal Growth Factor Serum Application	28

8 weeks : Yes adverse event

Group	Value	95% CI
Epidermal Growth Factor Serum Application	0

Sponsor's own description

EGF is a polypeptide that promotes cell differentiation and collagen production while decreasing melanin production. This study is designed to study its effectiveness in improving the texture and appearance of facial skin after daily topical application. We hypothesized that EGF would improve facial skin hydration, elasticity, pigmentation, and wrinkles.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical Measurement of Transepidermal Water Loss.
Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148

Verify or expand the search:

Other trials of Epidermal Growth Factor

Trials testing the same drug.

NCT06044974 — Nd-YAG Laser Versus Epidermal Growth Factor For Myogenic Tempromandibular Disorder. · Phase 4 · completed

Other recruiting trials for Aging

Currently open trials in the same condition.

NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
NCT07099053 — Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging · recruiting
NCT07504068 — Effects of Physical Exercise and a Nutritional Supplement on Body Composition, Metabolic Function, and Overall Health in · NA · recruiting
NCT07525453 — Effects of Three Different Exercise Programs on Dynamic Balance in Community-Dwelling Older Adults · NA · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other Institute of Dermatology, Thailand trials

Trials by the same sponsor.

NCT07536100 — VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia · NA · not yet recruiting
NCT07503197 — A Pilot Study on the Efficacy of 2% Cholesterol Cream in Preventing Transepidermal Water Loss and Clinical Symptoms in M · NA · enrolling by invitation
NCT07433907 — Efficacy of an Antioxidant Moisturizing Serum for Mild to Moderate Seborrheic Dermatitis · NA · recruiting
NCT06202560 — Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study · NA · completed
NCT03926845 — Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05724589 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Dermatology, Thailand
Last refreshed: 31 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05724589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT05724589

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of Epidermal Growth Factor

Other recruiting trials for Aging

Other Institute of Dermatology, Thailand trials

Verify against primary sources